Aviptadil Acetate
Code | Size | Price |
---|
TAR-TP1016L-1mg | 1mg | £138.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP1016L-5mg | 5mg | £213.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP1016L-10mg | 10mg | £303.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP1016L-25mg | 25mg | £463.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP1016L-50mg | 50mg | £621.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP1016L-100mg | 100mg | £849.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Avitadil acetate induces pulmonary vasodilation and inhibits the proliferation of vascular SMCs and platelet aggregation. Avitadil acetate can be used for research on pulmonary fibrosis, pulmonary hypertension (PAH), and respiratory failure caused by SARS-CoV-2.
CAS:
1444827-29-5
Formula:
C147H238N44O42S.C2H4O2
Molecular Weight:
3385.9
Pathway:
Microbiology/Virology; Endocrinology/Hormones
Purity:
1
SMILES:
HSDAVFTDNY TRLRKQMAVK KYLNSILN(acetate salt)
Target:
RAAS; SARS-CoV
References
Hu J , Xu Q , Mctiernan C , et al. Novel Targets of Drug Treatment for Pulmonary Hypertension[J]. American Journal of Cardiovascular Drugs, 2015, 15(4):225-234.
Frye BC, Meiss F, von Bubnoff D, Zissel G, M?ller-Quernheim J. Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis. N Engl J Med. 2020;382(26):2573-2574. doi:10.1056/NEJMc2000343